The Cardiac Biomarkers Market is strongly supported by troponin testing. Market Research Future identifies Troponins T and I as the largest type segment, accounting for approximately 42% of the market. Their high sensitivity and specificity make them important tools for detecting myocardial injury and supporting the diagnosis of heart attacks.

High-sensitivity troponin assays are improving the ability of healthcare professionals to detect cardiac injury at earlier stages. Faster testing can also support clinical decision-making in emergency settings.

Creatine kinase, myoglobin, BNPs, and ischemia-modified albumin provide additional options for assessing cardiovascular conditions. The development of multiplex testing platforms is creating opportunities to evaluate multiple biomarkers within a single diagnostic workflow.

As testing technologies become more sensitive and efficient, cardiac biomarkers are expected to play an increasingly important role in precision cardiovascular care.